ImmunoScape

We are thrilled to share that ImmunoScape has been awarded a $250,000 G-Rex® Grant from ScaleReady™, in collaboration with Wilson Wolf Manufacturing, LLC, Bio-Techne, and CellReady™. With this support, ImmunoScape will focus on pre-clinical milestones, including the scale up to a cGMP-compliant, closed-system manufacturing process. Get more details from our own Tânia C. in the press release below.

Our Senior Vice President of Discovery Dan MacLeod presented and co-chaired a workshop this week at the 9th CAR-TCR Summit in Boston. Stay tuned for more details on his presentation focused on applying machine learning to cell therapy discovery. #machinelearning #cartcr #immunology #tcells

Meet Andreas Wilm Andreas joined ImmunoScape in 2021 as Sr. Director of Computational Biology, where he leads a team that is responsible for data science and machine learning. He has worked at the intersection of technology, biology, and computer science for nearly 2 decades, most recently as a Cloud solution architect and Data & AI subject matter expert at Microsoft. At the Genome Institute of Singapore (GIS) of Singapore, Andreas developed scalable computational workflows for analyzing genomics big data on hybrid compute platforms. Learn more about how #machinelearning will transform the way therapeutics are discovered and developed for solid tumors. Q: What drives you? A: I love to apply technology to solve real world problems. In computational biology, we often need to develop the right tools in the first place and this process is very rewarding. Every new tool or programming library built is ultimately added to our toolkit, which allows us to develop solutions that can tackle new problems more efficiently.   Q: What’s one thing more people should understand about TCR-based therapies for cancer? A: T cells are a crucial part of our own immune system, and their receptors (TCRs) recognize so-called antigens (fragments of infected or abnormal cells). Upon recognition, T cells target and kill the affected cell. TCR-based therapies harness the incredible power of this precision machinery, and the drug discovery process can tap into the incredibly diverse repertoire of TCRs present in any human. TCRs can recognize many more antigens than other therapies, and hold significant potential for treating solid tumors, which are very hard to treat.   Q: How will Machine Learning transform the way new treatments are developed? A: ML will significantly enhance the development of new treatments for cancer and other diseases by accelerating drug discovery or optimization of clinical trials. Currently, there’s a lot of research focused on using AI to help accelerate or increase the chances of success of these infamously costly and time consuming clinical trials. One example is patient recruitment. With the optimization of eligibility criteria, more patients suitable for treatment can potentially be identified for inclusion.   A more mature application is in drug discovery. In our case, we apply ML methods to enhance the discovery of TCRs by analyzing complex, multimodal datasets from genomics and proteomics to identify novel therapeutics against solid tumors. These advanced analytical tools help in uncovering patterns and relationships that might be missed, or that are simply too laborious or slow to detect through conventional methods.   But ML/AI is not a silver bullet by itself. The focus must be on harnessing these methods to complement and enhance existing methodologies to ensure a more robust and efficient approach to tackling diseases.   #immunology #deepimmunomics #machinelearning #cancertherapeutics #tcells

Earlier this year, our senior scientist Juliana Velez Lujan, Ph.D. presented an abstract on how ImmunScape's can aid in the discovery and development of T Cell receptors targeting Melanoma-associated antigens (MAGE) for adoptive T Cell therapy against solid tumors. See the full poster to learn more about how discovering robust and specific MAGE-reactive TCRs remains challenging due to limited throughput of TCR screening methodologies and how our technology can help overcome those issues. #melanoma #solidtumors #immunology #tcells

ImmunoScape Director of Computational Biology Andreas Wilm presented an abstract at the AACR Annual Meeting earlier this year focused on how our validated bioinformatics tool-set can help solve the long-standing problem of predicting TCR specificity computationally. The poster presents three in-silico TCR discovery modules that are seamlessly integrated with ImmunoScape’s wet-lab and in-vitro validation platform and show validation examples for each. See the full poster here: https://lnkd.in/ekrwQ475 #immunology #tcells #computationalbiology #AACR

Meet Tânia C. Tania Catarino Ribeiro joined ImmunoScape in 2023 as Senior Director CMC, bringing more than 20 years’ education and leadership experience in cell and gene therapy. Learn about what motivates Tania, what she looks for in leadership and a lifelong goal outside of work she hopes to fulfill.   Q: What do you enjoy about working at growth-stage companies, and what is challenging? A: The dynamic environment, the fast pace, the constant challenges, and the collective enthusiasm of colleagues all contribute to an exhilarating atmosphere. However, navigating through ambiguity and adapting to rapid changes can be challenging.   Q: What makes a great team? A: What truly makes a great team is diversity of perspectives, backgrounds, and skill sets. A diverse team can foster creativity, innovation, and problem-solving – and also tackle challenges from multiple angles and achieve remarkable results. For example, ImmunoScape has leveraged this diversity to build a team of experts across the fields of oncology, cellular and molecular biology, immunotherapy, and computational biology. Our validated #DeepImmunomics and #MachineLearning platforms enable at scale selection of specific, safe and novel #TCR-based therapies. This discovery engine continuously generates unique TCR targets, allowing us to advance validated targets to the clinic. It’s exciting to see the results of our programs, which are demonstrating strong efficacy against solid tumors.   Q: What makes a great leader? A: A great leader possesses empathy, vision, and a clear sense of mission. Empathy allows leaders to understand and connect with their team members on a deeper level, fostering trust and collaboration. Vision enables leaders to inspire others and chart a course for the future, while a strong sense of mission gives purpose and direction to their leadership.   Q: How do you like to spend a lazy Sunday? A: I cherish lazy Sundays spent indulging in simple pleasures – curling up with a good book by the fireplace in winter, basking in the sun in summer, or enjoying outdoor activities like kayaking. I find solace in moments of relaxation and reflection.   Q: What do you want to accomplish outside of work? A: One of my lifelong aspirations is to become a doctor without borders. This childhood dream stems from a deep desire to make a meaningful impact on the lives of underserved communities around the world, particularly in Africa, a place that holds special significance due to my family roots. #immunology #deepimmunomics #cancertherapeutics #tcells

Have you registered for BIO 2024? Our CEO Choon-Peng (Choon) Ng, VP of Innovation Michael Fehlings and Senior Director of Business Development Christopher Alfonso will be representing ImmunoScape at this year's BIO International Convention in San Diego, CA. If you'd like to connect at the conference, please send us message. #BIO2024 #immunology #deepimmunomics #cancertherapeutics #tcells

ImmunoScape Scientist Hannah Fields recently presented an abstract at the AACR Annual Meeting focused on our Deep Immunomics pipeline for discovery and validation of novel cancer-specific T cell receptors. The poster highlights how TCRs elucidated from our pipeline cover a range of therapeutically relevant cancer-related antigen targets presented on six common HLA molecules. For full details, see the poster at the link below.   #immunology #tcells #therapeutics #immunomics #aacr

If you are headed to BioCentury Inc.'s BioEquity Europe Conference and are interested in learning how ImmunoScape is working toward the development of TCR-based therapies against solid tumors, send us a message. Our Co-founder and VP of Innovation Michael Fehlings will be on the ground and will be setting up meetings. #BioEquityEurope #biotech #drugdevelopment #businessdevelopment #pharma

Next-gen TCR-based therapies against solid tumors have the power to disrupt and transform the development, delivery, and efficacy for cancer patients. Dan Macleod, ImmunoScape’s SVP of Discovery, will be an expert speaker at this year’s TCR-based Therapies for Solid Tumors Summit in Boston. We look forward to joining the impressive line-up of innovators accelerating the development of TCR-based therapies against solid tumors.   Please join Dan’s talk if you’re attending this year’s summit! Check out the full agenda: https://lnkd.in/gF2zkg8 #machinelearning #therapeutics #immunotherapy #lifesciences #healthcare